Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Founder, Chairman of The Board and Chief Science Advisor
Executive Vice President of R&D
Executive Vice President of Commercial
Compensation as of Fiscal Year 2014.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology IP Limited Announces Revenue Results for the Year Ended September 30, 2014
Dec 2 14
Oxford Gene Technology IP Limited announced revenue results for the year ended September 30, 2014. For the period, the company reported total revenue grew by 27% to £15.2 million against £11.9 million a year ago.
Oxford Gene Technology Receives £200,000 Phase One Development SBRI Contract to Develop Innovative NGS Analysis Software
Jul 21 14
Oxford Gene Technology has been awarded a £200,000 phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition. The contract is to develop whole genome Next Generation Sequencing (NGS) analysis software to increase the accuracy, and enhance the analysis of genomic sequence data. This landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.
Oxford Gene Technology IP Limited Launches High-Resolution, High-Throughput PGS Array
Jul 8 14
Oxford Gene Technology IP Limited has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF). The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking — a common procedure for advanced maternal age samples — enabling the confident identification of the best embryo for implantation. The CytoSure Embryo Screen Array is sensitive enough to work with small amounts of amplified DNA from a single embryo cell. For optimal hybridisation and maximum accuracy, the probe design of the CytoSure array exactly mirrors only the amplified DNA; regions of the genome that have not been amplified are therefore not represented, minimising the possibility of misleading results. Oligonucleotide arrays, such as the CytoSure Embryo Screen Array, typically provide lower batch-to-batch variation than alternative bacterial artificial chromosome (BAC) arrays, enabling more reliable analysis. In addition, flexibility in design and content further enhances the ability of oligonucleotide arrays to meet future research requirements.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries